Managing Oncology Costs in Polycythemia VeraVideo Categories: Polycythemia Vera
Supported through funding from Incyte
Listen as Dr Agarwala describes the nuances of personalized medicine as they relate to melanoma and cutaneous malignancies.
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.